ArticleOncology research2026
Comparative Analysis of Tumor Microbiota Identifies a Metastatic-Specific Bacterial Signature, Highlighting
Article in Oncology research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cancer remains one of the leading global health challenges, with lung cancer (LC), breast cancer (BC), and colorectal cancer (CRC) among the most prevalent and deadly malignancies. The intratumoral microbiota (IM), a distinct microbial ecosystem within tumor tissues, has recently emerged as a potential modulator of carcinogenesis, immune responses, and metastatic progression. However, comparative cross-cancer analyses remain limited. Therefore, this study aimed to compare the IM across these cancer types, with particular emphasis on distinguishing metastatic from non-metastatic malignancies, to identify tumor-specific microbial signatures with potential relevance for biomarker discovery, patient stratification, and microbiota-informed therapeutic strategies. Methods: We performed 16S rRNA gene sequencing to profile the IM in formalin-fixed, paraffin-embedded (FFPE) samples from 20 BC patients, 20 CRC patients and 15 non-small cell lung cancer (NSCLC) patients. Results: BC samples exhibited the highest genus-level richness, whereas CRC samples showed significantly greater overall alpha diversity, consistent with the microbial complexity of the gut environment. NSCLC samples displayed the most balanced microbial distribution, as reflected by the highest Shannon index value. Stratification by metastatic status revealed distinct microbial signatures: 16 genera were exclusive to metastatic tumors and 49 to non-metastatic ones. In BC specifically, the class Clostridia and the family Burkholderiaceae were enriched in non-metastatic samples, accompanied by functional shifts in pantothenate and coenzyme A biosynthesis, lysine metabolism, and lipid A pathways. Microbial network analysis further revealed differences in ecological community structure and keystone taxa: Conclusions: Overall, our findings highlight cancer-type and metastasis-specific microbial signatures, supporting a potential role for the IM in tumor progression and offering novel avenues for biomarker discovery and therapeutic targeting.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.